Microdissected “cuboids” as a model system for cancer drug testing

Thursday, October 12, 2023

8:30 AM – 8:45 AM PDT

Location: 342 (Center, Level 3)

Presenting Author(s)

Lisa Horowitz, MD PhD

Research Scientist
University of Washington
Seattle, Washington, United States

Co-Author(s)

Tran Ngoc Huyen Nguyen, PhD (she/her/hers)

Postdoctoral Fellow
University of Washington
Seattle, Washington, United States
Ethan Lockhart

Graduate Research Assistant
University of Washington
SEATTLE, Washington, United States
RR

Ricard Rodriguez

University of Washington, United States
CL

Chuan Bian Lim

Human Biology Division, Fred Hutchinson Cancer Research Center, United States
HK

Heidi Kenerson

University of Washington, United States
JV

Judit Villen

University of Washington, United States
RY

Raymond S Yeung, MD

University of Washington, United States
TG

Taranjit Gujral

Fred Hutch Cancer Center, United States

Last Author(s)

AF

Albert Folch

Professor of Bioengineering
University of Washington, Washington, United States

Microdissected tumors (MDTs) have shown promise recently as an approach to cancer drug testing that preserves the tumor microenvironment (TME) and that can be combined with microfluidic multiplexing. We have used a microfluidic device with hydrodynamic traps to culture and perform 3D immunostaining and imaging of mouse and human cancer regular-sized MDTs, or "cuboids", as well as to perform drug testing . We further demonstrate the utility of the cuboid intact tissue model with off-device experiments with drug responses to a kinase inhibitor panel and to an immune checkpoint inhibitor, and with proteomic analysis of cuboids after drug treatment.